December 14, 2015

No Image

Serena Williams Wins Sportsperson Of The Year; Poll Favored American Pharoah

Serena Williams is Sports Illustrated's 2015 Sportsperson of the Year.

Serena Williams is Sports Illustrated’s 2015 Sportsperson of the Year. Bullit Marquez/AP hide caption

toggle caption Bullit Marquez/AP

Serena Williams, one of the greatest athletes in the world, had one of the greatest years in sports. For this, Sports Illustrated named her the 2015 Sportsperson of the Year. The article highlighted some of her achievements:

“Williams, 34, won three major titles, went 53–3 and provided at least one new measure of her tyrannical three-year reign at No. 1. For six weeks this summer—and for the first time in the 40-year history of the WTA rankings—Williams amassed twice as many ranking points as the world No. 2; at one point that gap grew larger than the one between No. 2 and No. 1,000. Williams’s 21 career Grand Slam singles titles are just one short of Steffi Graf’s Open-era record. Such numbers are reason enough for Sports Illustrated to name Serena Williams its 2015 Sportsperson of the Year.”

Williams is the first black woman to win the award solo.

Normally, that’s where the story would end. Instead, horse-racing fans made themselves heard, complaining that the Triple Crown-winning thoroughbred American Pharoah was snubbed. Here’s a sampling from those who felt the horse should have won Sportsperson of the Year:

@SInow @SI_ChrisStone @serenawilliams American Pharoah is the winner-hands down. You people are ridiculous.

— Looise (@Looise1) December 14, 2015

Very disappointed to see Sport’s Illustrated editors ignored the fans vote, and chose Serena Williams over American Pharoah – Article coming

— Brian Zipse (@Zipseatthetrack) December 14, 2015

Total BS @SInow @SITimLayden Why have a poll if you totally ignore it? Serena FAILED at winning the Grand Slam. AP once in a lifetime horse

— Justin Zayat (@JustinZayat) December 14, 2015

Much of the online outrage centered on the fact that Sports Illustrated had polled readers about whom they thought deserved the award, and American Pharoah received the most votes. In reality, the poll had no bearing on who would actually be honored.

The disagreement ballooned from there. The Los Angeles Times wrote an article called “Are fans right to be upset that Serena Williams beat American Pharoah for SI Sportsperson of the Year?” in which it earnestly dissected the criteria for winning the award:

“SI states that the sportsperson of the year award goes to ‘the athlete or team whose performance that year embodies the spirit of sportsmanship and achievement.’ That puts American Pharoah at a clear disadvantage since horses can’t really display sportsmanship.”

Implicit in the discussion about who deserved to win the award is the disconcerting comparison between a black woman and a horse. It’s an offensive and ill-advised comparison, but one that was made explicitly throughout the day:

Serena Williams or American Pharoah: Who’s the real sportsperson of 2015? Vote in our poll https://t.co/l4A51SPUlP pic.twitter.com/dssxaGFbAn

— Los Angeles Times (@latimes) December 14, 2015

The comparison also harkens back to the 1940s when black Olympic athlete Jesse Owens raced against horses to make money.

This reminds me of when Jesse Owens was made to race a horse to earn living expenses: https://t.co/XypyJCPyom. https://t.co/1L2fV9dAYR

— stacia l. brown (@slb79) December 14, 2015

#JesseOwens, w/4 gold medals still had to race vs a #horse to entertain & justify his talent. “What was I supposed to do?” @Semhar @latimes

— Maaza Mengiste (@MaazaMengiste) December 14, 2015

The Bismarck Tribune wrote about Owens in 2013:

“At the 1936 Olympics, he brought pride to America and shattered Adolf Hitler’s claim of Aryan superiority by winning four gold medals in track and field. However, racism existed in America, and there were no endorsements and very few meaningful job opportunities for Owens, an African American. He found that he needed to turn to carnival-like gimmicks to earn a living.”

On Monday, Sports Illustrated published another article, explaining that the decision to choose Williams was based not just on her impressive record but also on her endeavors off the court, including her willingness to confront social issues.

“We are honoring Serena Williams too for reasons that hang in the grayer, less comfortable ether, where issues such as race and femininity collide with the games. Race was used as a cudgel against Williams at Indian Wells in 2001, and she returned the blow with a 14-year self-exile from the tournament. She returned to Indian Wells in ’15, a conciliator seeking to raise the level of discourse about hard questions, the hardest ones, really.”

That is something American Pharoah could never do.

This entry passed through the Full-Text RSS service – if this is your content and you’re reading it on someone else’s site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.


No Image

Rout Continues In Junk Bond Market After 2 Funds Are Liquidated

The gloom deepened in the high-yield debt market on Monday, with bonds issued by dozens of companies losing ground, and concerns mounting about how long the rout will last.

Bonds issued by lower-rated companies such as Dynegy, Charter Communications, Chesapeake Energy and Oasis Petroleum have taken a tumble, as have investment funds that trade in such debt.

“It could get pretty ugly this week,” Bank of America strategist Michael Contopoulos said, in an interview with Bloomberg News.

The downturn in the high-yield debt, or junk bond, market has intensified in recent days after two high-yield funds announced they were suspending investor withdrawals, because of losses.

Junk bonds have performed well in recent years, in part because central banks such as the U.S. Federal Reserve have kept interest rates so low. As a result, a lot of investors plowed their money into junk bonds, which pay better but are also riskier.

Now, however, the Fed is poised to raise interest rates, and the flow of money into the sector appears to be reversing.

Meanwhile, concern is building about the slowing global economy, and investors are worried that a lot of companies that borrowed in the junk bond market won’t be able to pay back what they owe. Oil and gas companies are especially threatened.

Jeff Tjornehoj, head of Americas research at Thomson Reuters Lipper, told The Wall Street Journal that “investors remained disappointed by returns” in the high-yield market:

“There hasn’t been a whole lot of great news as far as the economy or yields. The shocks to the system have more than offset the trickle of good news.”

Last week, the U.S. investment firm Third Avenue liquidated its Focused Credit Fund and told investors it was suspending redemptions, meaning investors were temporarily barred from getting their money back. The company fired its chief executive, David Barse.

The hedge fund Stone Lion Capital Partners also said it was barring redemptions from one of its funds.

“The closures highlight an area of growing concern: the impact of investor flows on bond prices and the ability of companies to raise finance,” noted The Financial Times. It added:

“High-yield mutual funds, which face the first year of widespread losses since 2008, must return capital on demand. So the risk is that a need to sell bonds to meet redemptions pushes down prices, prompting further fund redemptions.”

With so much uncertainty in the market, Lucidus Capital Partners, a high-yield hedge fund, said Monday that it has liquidated its entire portfolio and will return the $900 million it has under management to investors next month.

“The risk is that this is going to cascade into something bigger,” Scott Minerd, global chief investment officer at Guggenheim Partners, told Bloomberg News on Friday. As investors worry about getting their money back, 10 to 15 percent of junk bond funds could face high withdrawals, he said.

“If we’re going to see contagion, the most vulnerable funds are going to be the ones that are down significantly,” said Minerd.

This entry passed through the Full-Text RSS service – if this is your content and you’re reading it on someone else’s site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.


No Image

You Can Buy Insulin Without A Prescription, But Should You?

Carmen Smith now gets the insulin she needs via her doctor's prescription. When she lacked health insurance, buying a version of the medicine over the counter was cheaper, she says. But it was hard to get the dose right.
4:48

Download

Carmen Smith now gets the insulin she needs via her doctor’s prescription. When she lacked health insurance, buying a version of the medicine over the counter was cheaper, she says. But it was hard to get the dose right. Lynn Ischay for NPR hide caption

toggle caption Lynn Ischay for NPR

As anyone with diabetes can tell you, managing the disease with insulin usually means regular checkups at the doctor’s office to fine-tune the dosage, monitor blood-sugar levels and check for complications.

But here’s a little known fact: Some forms of insulin can be bought without a prescription.

Carmen Smith did that for six years when she didn’t have health insurance and didn’t have a primary care doctor. She bought her insulin without a prescription at Wal-Mart.

“It’s not like we go in our trench coat and a top hat, saying, ‘Uh I need the insulin,’ ” says Smith, who lives in Cleveland. “The clerks usually don’t know it’s a big secret. They’ll just go, ‘Do we sell over-the-counter insulin?’ “

Once the pharmacist says yes, the clerk just goes to get it, Smith says. “And you purchase it and go about your business.”

But it’s still a pretty uncommon purchase.

Smith keeps the tools for controlling her diabetes in this kit, which contains metformin, syringes, fast-acting insulin for daytime use and slow-release for overnight.

Smith keeps the tools for controlling her diabetes in this kit, which contains metformin, syringes, fast-acting insulin for daytime use and slow-release for overnight. Lynn Ischay for NPR hide caption

toggle caption Lynn Ischay for NPR

Smith didn’t learn from a doctor that she could buy insulin that way. In fact, many doctors don’t know it’s possible. When she no longer had insurance to help pay for doctors’ appointments or medicine, Smith happened to ask at Wal-Mart if she could get vials of the medicine without a prescription. To figure out the dose, she just used the same amount a doctor had given her years before.

It was a way to survive, she says, but no way to live. It was horrible when she didn’t get the size of the dose or the timing quite right.

“It’s a quick high and then, it’s a down,” Smith says. “The down part is, you feel icky. You feel lifeless. You feel pain. And the cramps are so intense — till you can’t walk, you can’t sit, you can’t stand.”

Smith says her guesswork put her in the emergency room a handful of times over the years.

The availability of insulin over the counter presents a real conundrum. As Smith’s experience shows, without training or guidance from a health care provider, it can be dangerous for a patient to guess at the best dosage and timing from version to version of insulin. On the other hand, being able to afford and easily buy some when she needed it may have saved her life.

There are two types of human insulin available over the counter; one made by Eli Lilly and the other by Novo Nordisk. These versions of the medicine are older, and take longer to metabolize than some of the newer, prescription versions; they were created in the early 1980s, and the prices range from more than $200 a vial to as little as $25, depending on where you buy them.

Dr. Jorge Calles, an endocrinologist at MetroHealth, Cleveland’s public hospital, is alarmed to think that some people are self-medicating with any sort of insulin.

“It’s a very serious situation if they are selling it over the counter — without any control with a prescription, specifically,” Calles says.

According to the medical consulting firm IMS Health, about 15 percent of people who buy insulin in the growing U.S. diabetes market purchase it over the counter without a prescription.

The U.S. Food and Drug Administration declined multiple requests by NPR for an interview on this topic. But, in an email, an FDA representative said that the versions of insulin now available over the counter were approved for sale that way because they are based on a less concentrated, older formulation, “that did not require a licensed medical practitioner’s supervision for safe use.”

The broader availability of this form of insulin allows patients with diabetes to obtain it “quickly in urgent situations, without delays,” the FDA says, and is intended to increase patient safety.

Still, some people with diabetes, as well as some doctors, doubt that the benefits of that greater availability outweigh the risks, especially for patients who switch from one type of insulin to another without telling their doctor.

“This is not something that should be done without the help of a professional,” says David Kliff, who has Type 1 diabetes and writes the Diabetic Investors blog. Kliff has followed and written about the expanding business of diabetes for years.

FDA officials are “basically sticking their heads in the sand” on this issue, Kliff says, and making a lot of assumptions.

“They look at insulin as a drug,” he says, “and say, ‘There’s this enormous body of evidence that shows that the drug is safe.’ But, you know, there’s a little asterisk at the end there. What the little asterisk basically says is: ‘You know, that’s assuming that the patient is trained on it.’ “

When asked about safety concerns, the FDA told NPR that the agency welcomes more research into the safety of over-the-counter insulin.

One state does require prescriptions for all insulin. Dr. Kevin Burke, a health officer for Clark County, Ind., led the effort to require prescriptions in his state.

“I didn’t realize that insulin was over the counter in Indiana until two of my patients, who were in good control, suddenly had increased glucoses,” Burke says. He asked them if they had changed their diet, lost weight, altered their workout routines. They had not.

“They both admitted that they had decided to switch to over-the-counter insulin,” Burke says, “which was different from what I had prescribed.”

Over time, taking the wrong dosages destroys your body, Burke says. Poorly managed diabetes is the cause of a host of complications, such as high blood pressure, kidney disease, nerve damage, loss of eyesight and stroke.

Burke says he took his concerns to the American Medical Association. But the national doctor’s association told him there are no data showing that the drug’s over-the counter availability is a public health hazard. In fact, the AMA’s board noted, getting insulin without a doctor’s prescription may be an important way for some insulin-dependent patients to get access to the medicine they need.

Dr. Todd Hobbs is chief medical officer of Novo Nordisk in North America, which makes Novolin, one of the two versions of insulin sold over the counter. His company partners with Wal-Mart to sell its version under the brand name ReliOn. (Wal-Mart declined to be interviewed for this story.)

Hobbs says Novo Nordisk’s version of insulin is for people who don’t have insurance, or who have to pay a lot for their other prescriptions — “people who just, for whatever reason, have fallen through the cracks and either don’t have insurance coverage at the time or are without coverage.”

With ever-rising copays and premiums, he says, many patients are turning to nonprescription insulin because it’s cheaper and all they can afford.

“But we hope to try to help them to not have to do that,” Hobbs says.

“We clearly think the newer versions are more close to what the body would do on its own,” he says. The prescription versions are better and safer, he agrees, because they make it easier for patients to avoid wild fluctuations in blood sugar.

Carmen Smith doesn’t blame the insulin she was taking for her emergency room visits.

“Insulin is not the problem,” she says. “It is getting the insulin that is the problem. Once I got connected with my physician, life as a diabetic got a lot less complicated for me.”

Smith is now on Medicaid. She has a doctor — and a prescription for one of the newer generations of insulin.

This story is part of NPR’s reporting partnership with WCPN ideastream and Kaiser Health News.

This entry passed through the Full-Text RSS service – if this is your content and you’re reading it on someone else’s site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.